- Phase 3 ALOFT-PPF trial is studying admilparant in progressive pulmonary fibrosis
- Topline results anticipated in early 2027
- Companion to ALOFT-IPF trial which met primary endpoint at 60 mg dose
- Bristol-Myers Squibb announced that its Phase 3 ALOFT-PPF trial evaluating admilparant in progressive pulmonary fibrosis is ongoing, with topline results expected in early 2027.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card